journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://read.qxmd.com/read/30885459/should-we-expand-the-carbon-ion-footprint-of-prostate-cancer
#1
Charles N Catton, David B Shultz
No abstract text is available yet for this article.
March 15, 2019: Lancet Oncology
https://read.qxmd.com/read/30885458/risk-of-subsequent-primary-cancers-after-carbon-ion-radiotherapy-photon-radiotherapy-or-surgery-for-localised-prostate-cancer-a-propensity-score-weighted-retrospective-cohort-study
#2
Osama Mohamad, Takahiro Tabuchi, Yuki Nitta, Akihiro Nomoto, Akira Sato, Goro Kasuya, Hirokazu Makishima, Hak Choy, Shigeru Yamada, Toshitaka Morishima, Hiroshi Tsuji, Isao Miyashiro, Tadashi Kamada
BACKGROUND: The risk of subsequent primary cancers in patients with prostate cancer after treatment with photon radiotherapy is small in absolute numbers, but it is higher than that after surgical treatment. Carbon ion radiotherapy has a theoretically lower risk of inducing secondary malignancies than photon radiotherapy, but this risk has not been investigated in practice because of the low number of facilities offering such therapy worldwide and the limited data on long-term follow-up because the therapy has only been available since 1994...
March 15, 2019: Lancet Oncology
https://read.qxmd.com/read/30880072/olaparib-and-%C3%AE-specific-pi3k-inhibitor-alpelisib-for-patients-with-epithelial-ovarian-cancer-a-dose-escalation-and-dose-expansion-phase-1b-trial
#3
Panagiotis A Konstantinopoulos, William T Barry, Michael Birrer, Shannon N Westin, Karen A Cadoo, Geoffrey I Shapiro, Erica L Mayer, Roisin E O'Cearbhaill, Robert L Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K Buss, Carol Aghajanian, Gordon B Mills, Sangeetha Palakurthi, Paul Kirschmeier, Joyce Liu, Lewis C Cantley, Scott H Kaufmann, Elizabeth M Swisher, Alan D D'Andrea, Eric Winer, Gerburg M Wulf, Ursula A Matulonis
BACKGROUND: Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination repair (HRR) pathway (such as PI3K inhibitors) might sensitise HRR-proficient epithelial ovarian cancers to PARP inhibitors. We aimed to assess the safety and identify the recommended phase 2 dose of the PARP inhibitor olaparib in combination with the PI3K inhibitor alpelisib in patients with epithelial ovarian cancer and in patients with breast cancer...
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30880071/surufatinib-in-neuroendocrine-tumours
#4
Manjulika Das
No abstract text is available yet for this article.
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30880070/predictive-value-of-single-nucleotide-polymorphism-signature-for-recurrence-in-localised-renal-cell-carcinoma-a-retrospective-analysis-and-multicentre-validation-study
#5
Jin-Huan Wei, Zi-Hao Feng, Yun Cao, Hong-Wei Zhao, Zhen-Hua Chen, Bing Liao, Qing Wang, Hui Han, Jin Zhang, Yun-Ze Xu, Bo Li, Ji-Tao Wu, Gui-Mei Qu, Guo-Ping Wang, Cong Liu, Wei Xue, Qiang Liu, Jun Lu, Cai-Xia Li, Pei-Xing Li, Zhi-Ling Zhang, Hao-Hua Yao, Yi-Hui Pan, Wen-Fang Chen, Dan Xie, Lei Shi, Zhen-Li Gao, Yi-Ran Huang, Fang-Jian Zhou, Shao-Gang Wang, Zhi-Ping Liu, Wei Chen, Jun-Hang Luo
BACKGROUND: Identification of high-risk localised renal cell carcinoma is key for the selection of patients for adjuvant treatment who are at truly higher risk of reccurrence. We developed a classifier based on single-nucleotide polymorphisms (SNPs) to improve the predictive accuracy for renal cell carcinoma recurrence and investigated whether intratumour heterogeneity affected the precision of the classifier. METHODS: In this retrospective analysis and multicentre validation study, we used paraffin-embedded specimens from the training set of 227 patients from Sun Yat-sen University (Guangzhou, Guangdong, China) with localised clear cell renal cell carcinoma to examine 44 potential recurrence-associated SNPs, which were identified by exploratory bioinformatics analyses of a genome-wide association study from The Cancer Genome Atlas (TCGA) Kidney Renal Clear Cell Carcinoma (KIRC) dataset (n=114, 906 600 SNPs)...
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30880069/predicting-recurrence-in-patients-with-localised-renal-cell-carcinoma-after-nephrectomy
#6
Yair Lotan, Vitaly Margulis
No abstract text is available yet for this article.
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30880068/extending-the-scope-of-parp-inhibitors-in-ovarian-cancer
#7
Jonathan A Ledermann
No abstract text is available yet for this article.
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30880067/tobacco-consumption-in-bangladesh
#8
Talha Khan Burki
No abstract text is available yet for this article.
March 14, 2019: Lancet Oncology
https://read.qxmd.com/read/30857958/precision-oncology-giveth-and-precision-oncology-taketh-away
#9
Leonard B Saltz
No abstract text is available yet for this article.
March 8, 2019: Lancet Oncology
https://read.qxmd.com/read/30857957/choosing-wisely-india-ten-low-value-or-harmful-practices-that-should-be-avoided-in-cancer-care
#10
REVIEW
C S Pramesh, Harit Chaturvedi, Vijay Anand Reddy, Tapan Saikia, Sushmita Ghoshal, Mrinalini Pandit, K Govind Babu, K V Ganpathy, Dhairyasheel Savant, Gunita Mitera, Richard Sullivan, Christopher M Booth
The Choosing Wisely India campaign was an initiative that was established to identify low-value or potentially harmful practices that are relevant to the Indian cancer health-care system. We undertook a multidisciplinary framework-driven consensus process to identify a list of low-value or harmful cancer practices that are frequently undertaken in India. A task force convened by the National Cancer Grid of India included Indian representatives from surgical, medical, and radiation oncology. Each specialty had representation from the private and public sectors...
March 8, 2019: Lancet Oncology
https://read.qxmd.com/read/30857956/pertuzumab-plus-trastuzumab-for-her2-amplified-metastatic-colorectal-cancer-mypathway-an-updated-report-from-a-multicentre-open-label-phase-2a-multiple-basket-study
#11
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Ari VanderWalde, Charles Swanton, Razelle Kurzrock, Howard Burris, Christopher Sweeney, Ron Bose, David R Spigel, Mary S Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John Hainsworth
BACKGROUND: Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer. METHODS: MyPathway is an ongoing, phase 2a, multiple basket study...
March 8, 2019: Lancet Oncology
https://read.qxmd.com/read/30853443/no-benefit-of-lymphadenectomy-for-advanced-ovarian-cancer
#12
Elizabeth Gourd
No abstract text is available yet for this article.
March 7, 2019: Lancet Oncology
https://read.qxmd.com/read/30846328/pet-oestrogen-receptor-imaging-ready-for-the-clinic
#13
David A Mankoff, Amy S Clark
No abstract text is available yet for this article.
March 4, 2019: Lancet Oncology
https://read.qxmd.com/read/30846327/diagnostic-accuracy-and-safety-of-16%C3%AE-18-f-fluoro-17%C3%AE-oestradiol-pet-ct-for-the-assessment-of-oestrogen-receptor-status-in-recurrent-or-metastatic-lesions-in-patients-with-breast-cancer-a-prospective-cohort-study
#14
Sun Young Chae, Sei Hyun Ahn, Sung-Bae Kim, Sangwon Han, Suk Hyun Lee, Seung Jun Oh, Sang Ju Lee, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Jisun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jeong Eun Kim, Seog-Young Kim, Woo Jung Choi, Hee Jung Shin, Gyungyub Gong, Hyo Sang Lee, Jung Bok Lee, Dae Hyuk Moon
BACKGROUND: A biopsy of first recurrence or metastatic disease is recommended to re-evaluate oestrogen receptor status in patients with breast cancer and to select appropriate treatment. However, retesting for oestrogen receptor status with rebiopsy is not always feasible, depending on lesion location and the risk associated with biopsy, and in these cases clinicians continue to treat patients according to the oestrogen receptor status of the primary tumour. Consequently suboptimal therapy might be offered to these patients...
March 4, 2019: Lancet Oncology
https://read.qxmd.com/read/30827748/sacituzumab-govitecan-hziy-for-triple-negative-breast-cancer
#15
Robert Stirrups
No abstract text is available yet for this article.
February 28, 2019: Lancet Oncology
https://read.qxmd.com/read/30827747/a-well-organised-effort-to-metastatic-non-clear-cell-renal-cell-carcinoma
#16
Paul Russo
No abstract text is available yet for this article.
February 28, 2019: Lancet Oncology
https://read.qxmd.com/read/30827746/cabozantinib-in-advanced-non-clear-cell-renal-cell-carcinoma-a-multicentre-retrospective-cohort-study
#17
Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tripathi, Russell Pachynski, Andrew W Hahn, JoAnn Hsu, Sumit A Shah, Elaine T Lam, Tracy L Rose, Anthony E Mega, Nicholas Vogelzang, Michael R Harrison, Amir Mortazavi, Elizabeth R Plimack, Ulka Vaishampayan, Hans Hammers, Saby George, Naomi Haas, Neeraj Agarwal, Sumanta K Pal, Sandy Srinivas, Benedito A Carneiro, Daniel Y C Heng, Dominick Bosse, Toni K Choueiri, Lauren C Harshman
BACKGROUND: Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma. METHODS: We did a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib during any treatment line at 22 centres: 21 in the USA and one in Belgium...
February 28, 2019: Lancet Oncology
https://read.qxmd.com/read/30824205/how-can-global-incidence-estimates-support-childhood-cancer-control
#18
Eva Steliarova-Foucher
No abstract text is available yet for this article.
February 26, 2019: Lancet Oncology
https://read.qxmd.com/read/30824204/estimating-the-total-incidence-of-global-childhood-cancer-a-simulation-based-analysis
#19
Zachary J Ward, Jennifer M Yeh, Nickhill Bhakta, A Lindsay Frazier, Rifat Atun
BACKGROUND: Accurate estimates of childhood cancer incidence are important for policy makers to inform priority setting and planning decisions. However, many countries do not have cancer registries that quantify the incidence of childhood cancer. Moreover, even when registries do exist, they might substantially underestimate the true incidence, since children with cancer might not be diagnosed. We therefore aimed to provide estimates of total childhood cancer incidence accounting for underdiagnosis...
February 26, 2019: Lancet Oncology
https://read.qxmd.com/read/30799262/10-year-performance-of-four-models-of-breast-cancer-risk-a-validation-study
#20
Mary Beth Terry, Yuyan Liao, Alice S Whittemore, Nicole Leoce, Richard Buchsbaum, Nur Zeinomar, Gillian S Dite, Wendy K Chung, Julia A Knight, Melissa C Southey, Roger L Milne, David Goldgar, Graham G Giles, Sue-Anne McLachlan, Michael L Friedlander, Prue C Weideman, Gord Glendon, Stephanie Nesci, Irene L Andrulis, Esther M John, Kelly-Anne Phillips, Mary B Daly, Saundra S Buys, John L Hopper, Robert J MacInnis
BACKGROUND: Independent validation is essential to justify use of models of breast cancer risk prediction and inform decisions about prevention options and screening. Few independent validations had been done using cohorts for common breast cancer risk prediction models, and those that have been done had small sample sizes and short follow-up periods, and used earlier versions of the prediction tools. We aimed to validate the relative performance of four commonly used models of breast cancer risk and assess the effect of limited data input on each one's performance...
February 21, 2019: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"